Vidcast: https://youtu.be/vDcsb8EVH6Y
Aspirin has now been shown to significantly improve survival for at least one type of cancer in those patients whose tumors have a specific genetic variant. That cancer is squamous cell carcinoma of the head and neck with an altered PIK3CA gene.
A study just published in The Journal of Experimental Medicine followed 266 patients after surgical resection of their tumors and post-operative chemotherapy and/or radiotherapy. Those patients regularly taking aspirin or another NSAID for 6 months and also having an activated PIK3CA gene were 3 times more likely to survive 5 years. Specifically, the average survival rate rose from a baseline of 25 percent to a gratifying 78 percent. Those without the PIK3CA gene mutation enjoyed no survival benefit.
A larger, confirmatory study is now underway. Meanwhile, know that the PIK3CA oncogene is present and mutated in about one-third of other cancers including colon, stomach, esophageal, pancreatic, liver, breast, cervical, endometrial, ovarian, brain, and skin but not melanoma. We don’t yet know if aspirin added to conventional therapy will improve survival in any of these, but studies should be forthcoming. One early study suggests that aspirin co-therapy dues not improve endometrial cancer treatment success.
If you have cancer, ask your oncologist about the mutations found in your tumor. If yours has the PIK3CA mutation, then ask about aspirin therapy. If you are having a a biopsy or surgery for any type of cancer, be certain that a genetic analysis is performed on the tumor tissue and and that it’s preserved for future genetic studies. Treatment based on cancer genetics is increasingly more common.
Matthew L. Hedberg, Jennifer R. Grandis, etal. Use of nonsteroidal anti-inflammatory drugs predicts improved patient survival for PIK3CA-altered head and neck cancer. The Journal of Experimental Medicine, 2019; jem.20181936 DOI: 10.1084/jem.20181936
Samuels Y, Waldman T. Oncogenic mutations of PIK3CA in human cancers. Curr Top Microbiol Immunol. 2010;347:21-41.
#cancer #aspirin #ibuprofen #NSAIDS